AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HAEMONETICS CORP Director's Dealing 2023

Oct 24, 2023

31565_dirs_2023-10-24_0e85bd68-60b2-46a6-aa74-c8518b7e3eaa.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2023-10-20

Reporting Person: Strong Stewart W (President, Global Hospital)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-10-20	Common Stock	F	120	$89.05	Disposed	16101	Direct

Footnotes

F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2: This number includes unvested RSUs previously reported.